Establishes a special registration for physicians to administer schedule I eligible investigational drugs under the Federal Right to Try law.
The Freedom to Heal Act of 2025 amends the Controlled Substances Act to create a special registration process for physicians who wish to administer schedule I eligible investigational drugs to eligible patients under the Federal Right to Try law. The Attorney General must register physicians who submit an application with required documentation, including evidence of compliance with the Federal Food, Drug, and Cosmetic Act and proof of state licensure to treat patients with investigational drugs.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.